| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Cyclo(Ala-Gly) does not have a single, well-defined pharmacological target. Its mechanism of action is not fully elucidated, but its cytotoxicity against cancer cell lines suggests it may interfere with essential cellular processes. As a cyclic dipeptide, it may interact with intracellular proteins or enzymes.
|
|---|---|
| ln Vitro |
In vitro, Cyclo(Ala-Gly) exhibits cytotoxicity against A549, HepG2, and HT29 cells. Its IC50 values range from 9.5 to 18.1 μM. It shows low toxicity to Artemia salina (LC50 > 100 μg/mL), indicating a degree of selectivity.
|
| ln Vivo |
In vivo activity of Cyclo(Ala-Gly) is not detailed in the provided search results. Its cytotoxic activity against cancer cells suggests potential for anticancer applications, but its in vivo efficacy and safety would need to be confirmed in animal models.
|
| Enzyme Assay |
Non-cellular assays for Cyclo(Ala-Gly) are not typical, as its primary activity is assessed in cell-based systems. However, its mechanism of action could be investigated using biochemical assays to identify its protein targets.
|
| Cell Assay |
In vitro cellular assays for Cyclo(Ala-Gly) are conducted in cancer cell lines, including A549, HepG2, and HT29. Cells are treated with the compound, and cell viability is measured using MTT or CellTiter-Glo assays to determine the IC50. Its effects on cell cycle and apoptosis can also be assessed.
|
| Animal Protocol |
In vivo animal experiments with Cyclo(Ala-Gly) are not detailed in the provided search results. If conducted, they would likely involve mouse xenograft models of cancer, where the compound would be administered, and tumor growth would be monitored.
|
| ADME/Pharmacokinetics |
Cyclo(Ala-Gly) has a molecular weight of 128.13. It is soluble in water and organic solvents. Its pharmacokinetic properties are not well-characterized. The compound is typically stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Cyclo(Ala-Gly) shows low toxicity to Artemia salina (LC50 > 100 μg/mL), but comprehensive toxicological data are not extensively published. The compound is intended for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
It has been reported that Aspergillus fumigatus contains cycloalanine and glycine, and there is relevant data on this.
Cyclo(Ala-Gly) is a natural cyclic dipeptide metabolite of Penicillium thomi. It exhibits cytotoxicity against A549, HepG2, and HT29 cancer cells (IC50 = 9.5-18.1 μM) and shows low toxicity to Artemia salina. It is used in cancer research as a potential lead compound. |
| Molecular Formula |
C₅H₈N₂O₂
|
|---|---|
| Molecular Weight |
128.13
|
| Exact Mass |
128.059
|
| CAS # |
4526-77-6
|
| PubChem CID |
7408474
|
| Appearance |
White to off-white solid powder
|
| Density |
1.149g/cm3
|
| Boiling Point |
495.7ºC at 760 mmHg
|
| Melting Point |
246-247ºC
|
| Flash Point |
256.9ºC
|
| Index of Refraction |
1.452
|
| LogP |
-0.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H]1C(=O)NCC(=O)N1
|
| InChi Key |
ICCHEGCKVBMSTF-VKHMYHEASA-N
|
| InChi Code |
InChI=1S/C5H8N2O2/c1-3-5(9)6-2-4(8)7-3/h3H,2H2,1H3,(H,6,9)(H,7,8)/t3-/m0/s1
|
| Chemical Name |
(3S)-3-methylpiperazine-2,5-dione
|
| Synonyms |
Cyclo(AlaGly); Cyclo(Ala Gly)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~195.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (19.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (19.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.8046 mL | 39.0229 mL | 78.0457 mL | |
| 5 mM | 1.5609 mL | 7.8046 mL | 15.6091 mL | |
| 10 mM | 0.7805 mL | 3.9023 mL | 7.8046 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
